CL2A-SN-38是drug-linkerconjugate，由linkerCL2A和毒性分子SN-38连接而成的，可用来制备抗体偶联药物。CL2A-SN-38针对人类实体瘤表现出特异性的抗肿瘤作用。SN-38是一种DNATopoisomeraseI抑制剂。CL2A是一种不可降解(non-cleavable)的含PEG8-和三偶氮的PBC-肽-mclinker。CL2A通过pH敏感性降解，产生旁观者效应，并通过二硫键与抗体结合在半胱氨酸残基上。
货号:ajcx30414
CAS:1279680-68-0
分子式:C73H97N11O22
分子量：1480.61
溶解度:DMSO: 100 mg/mL (67.54 mM)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a nonclaevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond[1].

[1]. Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69.